Q3 Revenue Triples to $353M as Attruby Climbs; Three PDUFA Dates in Seven Months
BBIO sits 17% above its 52-week low of $60.22.
Summary
BridgeBio posted Q3 2026 total revenues of $353.2 million versus $120.7 million a year ago, with U.S. Attruby net product revenue of $253.2 million — up roughly $31 million sequentially and $145 million year over year. The quarter included a one-time $75.0 million BEYONTTRA sales milestone from Bayer, and the operating loss narrowed to $11.6 million from $145.2 million a year earlier, while net income was a loss of USD -60.496 million. Cash and marketable securities stood at $1.5 billion as of September 30, which management says fully funds all three launches and expansion indications. The setup into year-end is the regulatory calendar: BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, oral infigratinib for achondroplasia February 4, 2027, and encaleret for ADH1 May 8, 2027 — all under Priority Review, with field teams staffed. Also new this quarter: first participant dosed in the RECLAIM-HP Phase 3 for encaleret in chronic hypoparathyroidism (topline early 2028) and BBP-717 nominated as a development candidate for ATTR-CM with an IND planned for 2027. Attruby growth is coming from treatment-naïve starts, and the company keeps stacking real-world comparative data against tafamidis. Next hard catalyst is the BBP-418 FDA decision on November 27.
At the time of this announcement, BBIO was trading at $70.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.8B. The 52-week trading range was $60.22 to $93.42. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.